not clear with context-dependent effects of TGF-β1 described with in vitro and in vivo models of CAVD. In atherosclerosis, TGF-β1 leads to the activation of proteoglycan synthesis in vascular smooth muscle cells and induces elongation of the glycosaminoglycan (GAG) chains [33, 34] . Elongated GAG chains are capable of increased binding of lipid [34, 35] and this interaction underlies the "response to retention" hypothesis of Williams and Tabas regarding the origin of atherosclerosis [36] . In this study we investigated TβR signaling in diseased human aortic valves and the effects of TGF-β1 on por cine aortic valve interstitial cell proteoglycan synthesis and lipid binding to determine whether the proteoglycans produced by aortic valve interstitial cells could have a role in the initiation of the early sclerotic stage of CAVD.
Methods

Immunohistochemical analysis
Valve leaflets were fixed in 4% paraformaldehyde in 0.1M phosphate buffer overnight prior to processing. Radial cross-sections from intact leaflets were cut from annulus to free edge, embedded in paraffin, and cryosectioned in 5 -10 micron thick sections according to routine procedures. Immunohistochemistry was performed to evaluate distribution and expression of extracellular matrix components. Primary antibodies were to TGF-β1 (R&D Systems, 1:20) , and phosphorylated Smad2/3 (Chemicon, 1:1000). A universal streptavidin/biotin (Vector Laboratories, Burlingame, CA) and diaminobenzidine detection system (DAKO, Denmark) was used for colorimetric detection. Negative controls for all markers were performed in the absence of primary antibodies. Sections were counterstained with hematoxylin and images recorded using a Zeiss microscope with a Zeiss Axiocam digital camera (Germany). A total of seven tricuspid aortic valves were studied. Stenotic valves (three female 74, 75 and 82 y ears and two male 62 a nd 76 y ears) were obtained at valve replacement surgery and control valves (female 54 and male 73 years) were collected from hearts undergoing non-valve disease-related heart surgery as approved by the Alfred Hospital Ethics Committee (Prahran, Australia).
Isolation of aortic valve interstitial cells
Aortic valve interstitial cells (VICs) were isolated from porcine aortic valves collected from three pig hearts according to previously published methods [37] . Briefly, valve leaflets were dissected from the aortic root and rinsed in sterile PBS. To assist with removal of endothelial cells, partial digestion of the leaflets was performed with collagenase type II (2 mg/mL, Sigma-Aldrich, USA) in serum free DMEM (Invitrogen) for 20 minutes at 37 o C in an incubated shaker. Leaflet surfaces were then wiped with sterile swabs, cut into 1 mm pieces and placed into collagenase type III (2 mg/mL in DMEM) for 2-3 hours at 37 o C with shaking.
The digest was strained through a 100 micron filter and cells were pelleted. Cells were then dispersed in fresh medium (DMEM containing 5 mmol/L glucose, 10% FBS, 1% antibiotics), and plated in 75 cm 2 flasks. For experimentation, cells between passages one to four were used. Confluent cultures were serum-deprived by incubation in DMEM (5 mmol/L glucose, 0.1% FBS) for 48 hours prior to treatment. (an independent measure of GAG synthesis) treatment media was supplemented with methyl β-D-xylopyranoside (0.5 mmol/l, Sigma). Secreted proteoglycans were isolated and concentrated from the conditioned medium as described previously [34] . Radiolabel incorporation into proteoglycans was quantified using the CPC precipitation assay [38] . The sizes of the proteoglycans and GAG chains (cleaved chemically from the proteoglycan core proteins via a β-elimination reaction [39] ) were analysed by gradient SDS-PAGE [38] . GAG chain lengths also were analysed by size exclusion chromatography as described previously [40] and the data standardised by calculation of K av values.
Analysis of proteoglycans and glycosaminoglycans
Western blotting
Total cell lysates from VIC cultures treated with TGF-β1 (2 ng/ml) and/or SB431542 (3 µM) for 24 hours were resolved on 10% SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked with 5% skim milk powder for one hour at room temperature. Membranes were probed with primary antibodies as listed overnight at 4 o C and then incubated with species specific secondary HRP-IgG (1:5000, 1 hour, RT) followed by enhanced chemiluminescent detection of proteins (ECL, Amersham). To assess protein loading the membrane was reprobed with anti-smooth muscle α-actin mouse monoclonal antibody (Dako, 1:1000, 1 hour, RT) or anti-GAPDH rabbit monoclonal antibody (Cell Signaling, USA) followed by incubation with anti-mouse IgG (1:5000, 1 hour, RT) or antirabbit IgG (1:5000, 1 hour, RT) respectively. Antibodies to phosphorylated-Smad2,-Smad2C
and -Smad2L were obtained from Cell Signaling (USA).
Gel mobility shift assay
Quiescent VICs were treated with SB431542 (3 µmol/L) and TGF-β1 (2 ng/mL) for 24 hours in the presence of [ 35 S]-Met/Cys (1.85 MBq/mL) to radiolabel the proteoglycan core proteins. Increasing concentrations of LDL (0-0.5 mg/mL) purified by ultracentrifugation from human blood [41] were incubated with equal counts (1250 cpm) of proteoglycans. Bound and free proteoglycans were separated on flat bed agarose gels as described previously. [40] Dried agarose gels were exposed to phosphorscreens and calculation of bound proteoglycans was performed using MacBas software (v1, Fuji Photo Film Co., Japan).
Data analyses
Western blots were in triplicate and density analysis performed using Image Lab (BioRad). All data for proteoglycan experiments were collected in triplicate from at least two separate experiments. Data were calculated as means and standard errors and were compared using one-way ANOVA, two-way ANOVA, or Student's t-tests as indicated, with significance accepted at p<0.05. Figure 1 ). In all of the diseased valves TGF-β1 staining was seen throughout the markedly thickened layers and the strongest expression was found in close proximity to calcific nodules ( Figure 1B) . Examination of the stained valves at higher magnification showed diffuse strong intracellular and extracellular staining in the spongiosa region for TGF-β1 (data not shown).
RESULTS
Expression
The calcific remnants were stained dark purple by haematoxylin. A similar distribution of pSmad2/3 staining was visible in CAVD valves and prominent nuclear staining was also evident ( Figure 1D ). In contrast all of the non-diseased valve leaflets had much lower levels of TGF-β1 ( Figure 1A ) and less intense pSmad2/3 staining with less prominent nuclear staining ( Figure 1C ). Thus in the calcific stages of CAVD we observed staining that indicates an activated TβR -Smad2/3 pathway in the valves.
TGF-β1 mediates phosphorylation of Smad2/3 in aortic valve interstitial cells
As it remains technically difficult to demonstrate the activity of the TβR -Smad2/3 pathway in situ at the initiation stages of CAVD due to the lack of availability of suitable 
Antagonism of TβR1 inhibits TGF-β1 mediated proteoglycan synthesis and GAG elongation
In previous studies we and others have shown that activation of the TβR -Smad2/3 pathway increases proteoglycan synthesis in vascular smooth muscle cells and induces elongation of the glycosaminoglycan (GAG) chains and consequently greater lipid binding capacity [33, 34] . From our findings of TβR -Smad2/3 pathway activation in VICs we hypothesized that a similar upregulation of proteoglycan synthesis and GAG elongation may occur in these cells and potentially contribute to the thickening of valve cusps in CAVD.
To evaluate the involvement of the classic TGF-β1-mediated cell signalling pathway in proteoglycan synthesis VICs were stimulated with TGF-β1 (2 ng/mL) in the presence of
incorporation into proteoglycans in a dose-dependent manner, with data normalised to 0% and Figure 3D ). These data indicate that in this context phosphorylation of Smad2 rather than Smad3 mediates TGF-β1-induced proteoglycan synthesis.
To analyse whether the observed proteoglycan size changes were due to changes in GAG chain length, size exclusion chromatography was employed. Initially, GAG chains were chemically cleaved from proteoglycan core proteins via a β-elimination reaction and both complete proteoglycans and chemically cleaved GAG chains were separated by SDS-PAGE ( Figure 4A ). Under basal conditions, SB431542 treatment of VICs had negligible effect on the electrophoretic mobilities of either complete proteoglycans or cleaved GAG chains compared to control ( Figure 4A ). TGF-β1 treatment resulted in a decrease in electrophoretic mobility of both complete proteoglycans and cleaved GAG chains relative to control, which was attenuated in both cases in the presence of SB431542 ( Figure 4A ). Analysis of cleaved GAG chain length by size exclusion chromatography confirmed that the increase in GAG size demonstrated by SDS-PAGE was due to increased chain length. One representative analysis is shown in Figure 4B with the vertical line indicating mean K av of control and the combined results are shown in Table 1 . Under basal conditions, cleaved GAG chains derived from SB431542 treated VICs had a mean K av of 0.42±0.01 compared to 0.41±0.01 for control (Table 1 ). In the presence of TGF-β1, SB431542 treatment resulted in GAG chains with a mean K av of 0.41±0.01 compared to 0.36±0.01 for TGF-β1 treatment alone, p<0.02 (Table 1) indicating a stimulation of GAG elongation in the presence of TGF-β1 that was inhibited by SB431542.
Synthesis of GAG chains on a xyloside primer is a technique that allows evaluation of GAG synthesis independent of the proteoglycan core protein and was used to confirm TGF- 
DISCUSSION
The pathological and actively regulated disease processes of CAVD have been well recognised recently and understanding basic valve biology and signaling pathways of VICs is acknowledged as a high priority for progress in CAVD research [44] . Diseased valves have been shown previously to express the pleiotropic growth factor, TGF-β1 [32, 30, 45 ] and a mouse model of CAVD has demonstrated elevated levels of phosphorylated Smad transcription factors in aortic valves [46] . This study demonstrates that in human aortic valve lesions expression of both TGFβ1 and phosphorylated Smad2/3 are elevated throughout the thickened valve leaflets. Because TGF-β1 may be present in tissues in both active and latent forms, demonstrating the presence of TGF-β1 cannot determine whether the molecule is biologically active. However, canonical signaling by active TGF-β1 involves phosphorylation of Smad2/3 by TβR1 and subsequent translocation of pSmad2/3 to the nucleus. Thus, the demonstration that, in regions with immunostaining for TGF-β1, positive staining was also detected for both cytoplasmic and nuclear localization of pSmad2/3 provides supportive evidence of active TGF-β1 signalling in human aortic valve lesions. TGF-β1 and pSmad2/3 colocalization is also reported to occur in early lesions of the fibrosa in aortic valve leaflets from hypercholesterolemic pigs [47] . Significantly elevated levels of pSmad2/3 are also observed in mouse models of early stage CAVD [46] and after lipid lowering treatment in late stage CAVD mouse models [48] and underlines the key role Smad2/3 in CAVD processes.
We investigated the signaling pathways through which TGF-β1 mediates its effects in
VICs and demonstrated the involvement of the canonical Smad phosphorylation pathway. In porcine VICs TGF-β1 stimulated a significant increase in the level of both pSmad2/3C and pSmad2/3L. This specific response was blocked by SB431542, an inhibitor of the kinase activity of TβR1, for which both Smad2 and 3 are targets. Phosphorylation of Smad2/3 carboxy terminus was immediate and rapid, within 5 min, while linker region phosphorylation was elevated significantly after 30 minutes of TGF-β1 stimulation (Figure 2) . A similar differential in regional Smad2/3 phosphorylation is also seen in vascular smooth muscle cells [49] . Blocking pSmad2/3 phosphorylation inhibited proteoglycan GAG elongation however further studies are necessary to determine whether these downstream processes have a Our findings correlate with recent reports of activated Smad2/3 signaling with TGF-β1 treated porcine VICs grown in Wnt3A-conditioned media demonstrating induction of pSmad2/3 nuclear translocation [47] . The phosphorylation of Smad2/3 in aortic valves appears cell and context dependent since pSmad2 levels are not elevated in human aortic valve endothelium both in non-calcified and calcified valves [50] .
Recently it was highlighted that despite an abundance of proteglycans and GAGs in valves in CAVD the role of proteoglycans and GAGs has not been investigated [31] . Our study demonstrates that in porcine VICs TGF-β1 weakly induces proteoglycan core protein synthesis, and strongly stimulates proteoglycan GAG chain elongation. In addition we have clearly demonstrated that this is mediated by the classical TGF-β1 signaling pathway and by application of a pharmacological approach using SIS3 showed that Smad3 was not involved in proteoglycan synthesis, thereby demonstrating that the pathway specifically involves phosphorylation of Smad2. Previous in vitro studies using smooth muscle cells (SMCs) have demonstrated that TGF-β1 stimulates elongation of GAG chains on SMC-secreted proteoglycans [33] , specifically on the chondroitin sulfate (CS) /dermatan sulfate (DS)
proteoglycans, biglycan and decorin [33] and that these TGF-β1-induced changes in SMCproduced proteoglycans mediates increased lipoprotein binding [34] . In the present study we
show that TGF-β1 has similar effects on proteoglycans produced by aortic VICs. In VICs, TGF-β1 stimulated GAG chain elongation on CS/ DS proteoglycans, as well as elongation of the GAGs initiated on xyloside. Moreover proteoglycans synthesized in response to TGF-β1 demonstrate enhanced LDL binding, an effect that is blunted by inhibition of classical TGF-β1 signalling via Smad2. This finding demonstrates that TGF-β1 is acting on proteoglycans primarily at the level of the GAG synthesizing machinery in the Golgi apparatus, an effect that is independent of the presence of core proteins. TGF-β1 also appears to stimulate a small increase in total proteoglycan core proteins by aortic VICs; we speculate that this is most likely an increase in biglycan and/or decorin. Although in this study we did not formally evaluate which individual core proteins were increased because the apparent effect on core protein synthesis was small and because our major interest was in the more robust effect on GAGs and their binding to LDL. Specific proteoglycan identification may be useful considering the impact of extracellular matrix components on myofibroblast differentiation and behaviour in CAVD [51] . Biglycan and decorin are observed in early calcific nodule formation in human calcified aortic valves [29] and in late-stage CAVD there is increased accumulation of biglycan and with it a co-localization of oxidised-LDL, phospholipid transfer protein and Apo A1 [52] . By implicating biglycan and TGF-β1 influencing proteoglycan- In conclusion, our data confirm that TGF-β1 is present in diseased human aortic valves, extends this observation to demonstrate the presence of important components of the canonical TGF-β1 signalling pathway in these same valves, and elucidates how stimulation of specific TGF-β1 signaling pathways affects proteoglycan synthesis and lipoprotein binding in cultured porcine VICs. Together, these findings provide strong support to the proposal that CAVD is a complex, mechanism based disease that shares some similar pathogenic features with atherosclerosis. Tentative evidence is provided that lipid trapping by modified GAG chains on proteoglycans may also represent an early step in CAVD, as has been hypothesized [54] and strongly implicated by recent data [55] for atherosclerosis. Although we have demonstrated that the canonical Smad phosphorylation pathway is present in diseased human aortic valves and cultured porcine VICs, studies of TGF-β1 signaling pathways in emerging animal models of CAVD would be of great interest. Moreover, TGF-β1 is critically involved in the immune system, most likely through Smad-dependent pathways. Thus, notwithstanding the involvement of TGF-β1 in CAVD, blocking those pathways may not be an option for treating CAVD and atherosclerosis. However, recent evidence has shown that TGF-β1 signalling pathways are much more complex and can involve tyrosine and serine/threonine phosphorylation and activation of MAP kinases , particularly ERK and p38 [56] [57] [58] . This investigation demonstrated a small but not statistically significant level of MAP kinase activity in VICs associated with TGFβ1-mediated Smad phosphorylation however this may reflect the 4 hour time point studied. p38 MAP kinase is activated by angiotensin II within 15 mins in VICs [59] and ERK1/2 is phosphorylated in calcifying VIC cultures but to a lesser extent in the absence of calcification [60] . This suggests that MAP kinase activity can be induced at different stages of VIC activation. Taken together these observations raise a potential role for MAP kinase phosphorylation of Smads particularly in the Smad linker region. This might extend to an involvement of MAP kinase in the reported requirement of TGFβ1-induced pSmad2/3 and Wnt3A-induced β-catenin nuclear translocation in VIC myoblast differentiation [47] . In addition to Smad, Erk1/2 and p38 MAP kinases are involved in the regulation of GAG synthesis in vascular smooth muscle cells. [58, 49] . Therefore, further investigations may provide an opportunity to discover Smad-independent TGF-β1 mediated signaling pathways that are associated with diseases processes and not immune functions, and that may well serve as more therapeutically useful targets for CAVD prevention and provides further strong impetus for studying the potential positive and/or negative effects of inhibiting these pathways in animal models of CAVD. Alternatively, strategies that avoid interference with TGF-β1 signaling by directly targeting proteoglycan/lipoprotein interactions may also represent useful therapeutic goals in CAVD. (TGF-β+ SB) for 24h and proteoglycan core proteins were labelled with [ 35 S]-Met/Cys (50 µCi/ml). Equal counts of core protein-radiolabeled proteoglycans were combined with increasing concentrations of LDL and separated using the gel shift mobility assay. Three separate experiments were performed with data shown as mean ± SEM. ***p<0.001 using a 2-way interaction ANOVA comparing the two data sets. Earlier experiments using proteoglycans isolated from vascular smooth muscle cells showed the effect of SB431542 treatment alone on LDL binding is negligible (unpublished data). 
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